US stock futures inch lower after Wall St marks fresh records on tech gains
NutriBand Inc. (NASDAQ:NTRB), a healthcare company with a market capitalization of $72 million and strong liquidity position, disclosed Wednesday that a combination of stock options and warrants were exercised between February 1 and July 31, 2025, resulting in gross proceeds of approximately $5.35 million.
According to the company’s statement filed with the Securities and Exchange Commission, stock options covering 20,055 shares of common stock were exercised for a total price of $44,206. In addition, public warrants (NASDAQ:NTRBW) to purchase 47,076 shares of common stock were exercised for $302,699. Private investors exercised warrants to purchase 778,041 shares of common stock, generating $5,002,804 in proceeds.
The company’s common stock and public warrants are traded on the Nasdaq Stock Market under the symbols NTRB and NTRBW, respectively.
This information is based on a press release statement included in NutriBand’s recent SEC filing.
In other recent news, Nutriband Inc. has received approval from the U.S. Food and Drug Administration for a Type C Meeting to discuss its AVERSA FENTANYL abuse-deterrent transdermal system. This virtual meeting, set for September 18, 2025, will focus on the Chemistry, Manufacturing, and Controls plans for the product, from submission to potential commercialization. Additionally, Nutriband announced a 25% preferred stock dividend for shareholders, with a record date of July 25, 2025. Shareholders will receive one preferred share for every four common shares held, with distribution scheduled for August 5. The preferred shares will be convertible to common shares following FDA approval of the AVERSA Fentanyl product. Furthermore, the company’s board has authorized a new class of non-voting Series A Convertible Preferred Stock, allowing for the issuance of up to 2,788,678 shares. These developments are part of Nutriband’s strategic moves to enhance shareholder value and advance its product pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.